Pfizer to acquire Biohaven Pharmaceuticals

Pfizer says it will acquire New Haven-based Biohaven Pharmaceuticals, known for its migraine drug Nurtec ODT, for $11.6 billion cash.

“Pfizer’s capabilities will accelerate our mission to deliver our migraine medicines to even more patients,” said Vlad Coric, chairman and CEO of Biohaven. “We believe this transaction represents significant future value creation for patients and our collective shareholders.”

Pfizer news release
article in Hartford Business